Peter Attia· MD
do you only look at 10-year risk when it comes to ascbd which is kind of that medicine 2.0 approach or do you look at 50 or risk when it comes to that which is that 3.0 medicine 3.0 approach
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
do you only look at 10-year risk when it comes to ascbd which is kind of that medicine 2.0 approach or do you look at 50 or risk when it comes to that which is that 3.0 medicine 3.0 approach
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.